| Document |
Document Title |
|
WO/2020/233588A1 |
Disclosed are a new crystal form of a treprostinil sodium salt (the structural formula thereof is shown as formula I) and a preparation method therefor. Specifically, disclosed are a five and half hydrates of the treprostinil sodium salt...
|
|
WO/2020/234854A1 |
The present invention regards an ophthalmic composition comprising a mixture for use in a method for the treatment of a disorder or a disease associated with a corneal epithelial defect and/or a conjunctival defect in a subject.
|
|
WO/2020/230832A1 |
The present invention provides a method for purifying neural crest cells or corneal epithelial cells.
|
|
WO/2020/231198A1 |
The present invention relates to retinal disease prevention, treatment or remedial use of a gypenoside compound expressed by chemical formula (1). A composition comprising the compound or salts thereof effectively inhibits photoreceptor ...
|
|
WO/2020/229761A1 |
The invention relates to a pharmaceutical composition, comprising at least one compound of the echinocandin family and at least one other therapeutically active ingredient except for hypouricemic compounds, intended to be used as a cytop...
|
|
WO/2020/230869A1 |
The purpose of the present invention is to provide a composition for preventing or treating neurotrophic keratitis. It is found that PACAP peptide exerts an effect to prevent corneal damages in a neurotrophic keratitis model and can prom...
|
|
WO/2020/230251A1 |
This therapeutic agent for retinal diseases such as age-related macular degeneration contains, as an active ingredient, a sodium/glucose cotransporter 2 (SGLT2) inhibitory substance which is a phlorizin derivative such as canagliflozin, ...
|
|
WO/2020/230867A1 |
The purpose of the present invention is to provide a PACAP peptide having improved stability. The present invention is based on the finding that the stability of PACAP is significantly improved by substituting aspartic acid at positions ...
|
|
WO/2020/229538A1 |
At least one of oleuropein or metabolite thereof can be orally administered to an individual in an amount effective to achieve at least one result that is one or more of (i) improvement in a physiological state linked to metabolic fatigu...
|
|
WO/2020/226915A1 |
Pharmaceutical compositions for treating presbyopia are described, the compositions comprising choline esterase inhibitor(s) and several other components such as alpha-1-adrenergic antagonist(s), non-steroid anti-inflammatory drug(s), an...
|
|
WO/2020/225400A1 |
The present invention relates to antibodies and fragments thereof that target semaphorin 3A (Sema3A). More specifically, anti-Sema3A antibodies and methods of use for the treatment of various diseases or disorders are disclosed.
|
|
WO/2020/223933A1 |
Provided is an AAV mutant that efficiently infects supporting cells. Specifically, provided is a gene expression vector used for treating hearing disorders, and the described expression vector is an AAV mutant. In the AAV mutant, an expr...
|
|
WO/2020/221839A1 |
The invention relates to a specific composition comprising in particular at least gellan gum and phenylephrine. The invention also relates to a particular method for producing such a composition and to the uses thereof, in particular as ...
|
|
WO/2020/222195A1 |
Polymeric eye inserts are provided that may be dissolvable when placed in the cul-de-sac of the eye. These inserts may contain one or more polymers as well as a softener/plasticizer so that, when inserted into the eye, they may absorb te...
|
|
WO/2020/222189A1 |
This invention relates to a novel crystalline form of a compound of Formula (I), which is 6-{4-[1 -(propan-2 -yl)piperidin-4-yl]-1,4-diazepan-1 -yl}-N-(pyridin-4- yl)pyridine-2-carboxamide, and pharmaceutical compositions including the c...
|
|
WO/2020/223209A1 |
Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for eye conditions, for example, intraocular pressure, ocular hypertension, and glaucoma.
|
|
WO/2020/221832A1 |
The present invention relates to the field of therapeutic treatment of inherited retinal dystrophies, and in particular of syndromic Usher syndrome type 2 and non-syndromic retinitis pigmentosa, by genome engineering. Currently, no treat...
|
|
WO/2020/223158A1 |
Provided herein are methods and composition for trans-tympanic membrane delivery of therapeutic agents such as antimicrobial agents, anti-inflammatory agents, and anti-biofilm agents to the middle ear for rapid, localized treatment and p...
|
|
WO/2020/222892A1 |
Methods for immediate relief of migraine or headache are provided comprising the administration of an anti-CGRP antagonist antibody to a patient in need thereof. This invention pertains to methods of treatment of headache disorders, such...
|
|
WO/2020/222190A1 |
This invention relates to a novel crystalline form of a compound of Formula (I), which is 6-{4-[1 -(propan-2 -yl)piperidin-4-yl]-1,4-diazepan-1 -yl}-N-(pyridin-4- yl)pyridine-2-carboxamide, and pharmaceutical compositions including the c...
|
|
WO/2020/223169A1 |
The present invention invention provides HGF polypeptide variants, including dimers, for use in treatment, in particular to treat ocular diseases and disorders.
|
|
WO/2020/219264A1 |
The invention relates to methods of treatment of a patient with ferrochelatase inhibitors. In particular, the invention relates to methods of treatment of ocular diseases involving retinal neovascularization with ferrochelatase inhibitor...
|
|
WO/2020/216513A1 |
The present invention relates to methods of treating or preventing proliferative retinal disease.
|
|
WO/2020/218480A1 |
Provided is a composite that includes a neural retina, a retinal pigment epithelial cell sheet, and a hydrogel, wherein: the neural retina and the retinal pigment epithelial cell sheet are derived from human pluripotent stem cells; in th...
|
|
WO/2020/215164A1 |
Provided herein are methods and compositions for neuroprotection. The neuroprotective composition can be or include cannabinol or a derivative thereof. The neuroprotective composition can be used in the treatment of a neurodegenerative d...
|
|
WO/2020/219985A1 |
The present application is directed to the intravitreal use of spherical nucleic acid (SNA) molecules in the treatment of eye disorders including dry-eye, retinal edema, retinopathy, macular degeneration and glaucoma among others. SNAs h...
|
|
WO/2020/218466A1 |
The purpose of the present invention is to suppress the reduction of the percentage of the iodine content in an ophthalmic composition during storage. This ophthalmic product (A) according to the present invention is made by accommodatin...
|
|
WO/2020/218829A1 |
The present invention relates to a flagellin fusion protein and a use thereof and, more specifically, to a fusion protein comprising: flagellin, a fragment thereof, or a variant thereof; and an immunoglobulin Fc region, and a use in whic...
|
|
WO/2020/219977A1 |
Provided herein are methods and compositions for modulating expression of a target protein or a target RNA by modulating splicing pre-mRNA and for treating diseases or conditions associated with expression level of the target protein or ...
|
|
WO/2020/216240A1 |
The present invention belongs to the field of medicine, and specifically discloses a compound of formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and use thereof in the preparation of a me...
|
|
WO/2020/215968A1 |
Provided is a gene expression vector for treating a hearing impairment disease, wherein the expression vector is an AAV vector in which an expression cassette of a therapeutic gene for treating the hearing impairment disease is inserted ...
|
|
WO/2020/219634A1 |
Provided herein are methods of use of indole derivative compounds for reversal of amyloid β toxicity in amyloid β-associated diseases.
|
|
WO/2020/213693A1 |
The present disclosure provides a therapeutic or prophylactic agent for an ophthalmic disease such as presbyopia, said agent comprising, as an active ingredient, a lipoic acid prodrug having a specific structure.
|
|
WO/2020/211653A1 |
A cationic hyaluronic acid modified lipoid vesicle, comprising a drug-loaded vesicle. The surface of the drug-loaded vesicle is modified by cationic hyaluronic acid, the drug-loaded vesicle comprises a vesicle membrane and a hydrophobic ...
|
|
WO/2020/211751A1 |
The compound shown in formula I, and racemates, stereoisomers, tautomers, isotopic markers, nitrogen oxides, solvates, polymorphs, metabolites, esters, pharmaceutically acceptable salts, or prodrugs thereof. The compound shown in formula...
|
|
WO/2020/215094A1 |
Provided herein are 2-amino-pyrazolyl-[ 1,2,4]triazolo [1,5a]pyridine derivatives. Such compounds are useful, for example, for the treatment and/or prevention of neurodegenerative diseases or disorders such as ophthalmological neurodegen...
|
|
WO/2020/214799A1 |
The present disclosure relates to pharmaceutical suspensions of triamcinolone acetonide, methods of producing such suspensions and methods of using of such suspensions. The pharmaceutical suspensions of the present disclosure are stable ...
|
|
WO/2020/210248A1 |
The present application provides methods and processes for making and using a mesenchymal stem cell secretome, as well as methods for treating ocular conditions and/disorders with the mesenchymal stem cell secretome described herein.
|
|
WO/2020/210388A1 |
Provided herein are compound(s) for use in treating sensorineural hearing loss in a human patient, for example, hair cell regeneration agent(s) for use in treating sensorineural hearing loss in a human. Also provided are methods of treat...
|
|
WO/2020/210218A1 |
Provided herein are methods for treating an inherited eye disease or disorder through ex vivo introduction of a nucleic acid molecule into hematopoietic stem and progenitor cells (HSPCs) followed by transplantation of the HSPCs into a su...
|
|
WO/2020/208082A1 |
The present invention relates to the treatment of CMV related diseases. In a rat model of CMV infection of the developing brain in utero, the inventors recently detected prominent infection of brain immune cells and early neuroimmune def...
|
|
WO/2020/203822A1 |
The purpose of the preset invention is to provide a drug, which is useful for treating or preventing a retinal disease associated with angiogenesis and contributes to excellent medication compliance, or a combination therapy. The present...
|
|
WO/2020/201444A1 |
Provided herein are methods of use of 12 small molecules extracted from ZINC15 library for treating senescence-associated diseases and disorders by specifically targeting the FoxO4 protein. The diseases and disorders treatable with said ...
|
|
WO/2020/204001A1 |
Provided is a method for producing an aqueous suspension composition and the aqueous suspension composition, the method comprising a step A for preparing a mixture containing at least one selected from Rebamipide and a salt thereof; a wa...
|
|
WO/2020/203812A1 |
Provided is an inhibitor for a hypoxia-inducible factor (HIF). The HIF inhibitor may have low cytotoxicity and may be suitable for ophthalmological therapy. The present disclosure provides a composition that is for inhibiting a hypoxia-i...
|
|
WO/2020/200241A1 |
A use of beauvericin for preparing a medicament for treating an ocular disease such as age-related macular degeneration (AMD), diabetic retinopathy (DR) or macular edema (ME).
|
|
WO/2020/203086A1 |
[Problem] To provide an improved glucose-containing peritoneal dialysate, ophthalmic composition, or infusion that is not only capable of, as a result of simply being blended, suppressing an increase in the blood glucose level even when ...
|
|
WO/2020/202601A1 |
[Problem] The present invention addresses the problem of searching for and providing a novel acetylcholinesterase inhibitor. [Solution] The present invention provides an acetylcholinesterase inhibitor containing wood-tar creosote as an...
|
|
WO/2020/199460A1 |
Provided is the use of luteolin-7-O-glucoside or luteolin-7-O-glucuronide in the preparation of a medicine for eye injuries, wherein same falls within the technical field of medicines. Further provided is the use of luteolin-7-O-glucosid...
|
|
WO/2020/205801A1 |
Inhibitors of HIF can be used to treat ophthalmic conditions and diseases, such as infection, inflammation, glaucoma and retinal diseases, and other conditions such as stroke, injury to the central nervous system, traumatic brain injury,...
|
